

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Volume 15 Supplement 3 NOVEMBER/DECEMBER 2005

Contents

ARTICLES

- 195 The role of surgery in recurrent ovarian cancer
J. PFISTERER, P. HARTEK, U. CANZLER, B. RICHTER, C. JACKISCH, M. HAHMANN,
A. HASENBURG, A. BURGES, S. LOIBL, M. GROPP, J. HUOBER, D. FINK & A. DU BOIS
- 199 What is the role of conservative primary surgical management of epithelial ovarian cancer: the United States
experience and debate
B. J. MONK & P. J. DiSAIA
- 206 Role of conservative surgery in ovarian cancer: the European experience
N. COLOMBO, G. PARMA, M. T. LAPRESA, F. MAGGI, P. PIANTANIDA & A. MAGGIONI
- 212 Standard treatment in advanced ovarian cancer in 2005: the state of the art
M. A. BOOKMAN
- 221 First-line treatment of ovarian/tubal/peritoneal cancer FIGO stage IIB-IV with paclitaxel/carboplatin
with or without epirubicin (TEC vs TC). A gynecologic cancer intergroup study of the NSGO, EORTC GCG,
and NCIC CTG. Results on progression-free survival
G. B. KRISTENSEN, I. VERGOTE, G. STUART, J. M. DEL CAMPO, J. KÆRN, M. BAEKELANDT,
A. B. LOPEZ, H. HIRTE, E. AAVALL-LUNDQVIST, E. LORENZ & O. CERAR
- 222 Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO
stages IIB-IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial
E. PUJADE-LAURINE, A. DU BOIS, A. GOUPIL, J. ROCHON, V. MÖBUS, B. WEBER, S. OLBRICHT,
U. NITZ, M. WARM & B. RICHTER
- 224 Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II
study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9,
GINECO-TCG, NSGO-OC-0102) comparing TCG with standard TC
A. DU BOIS, J. SEHOULI, B. LUND, F. JOLY, J. HUOBER, T. S. JENSEN, E. LEVY, V. HEILMANN, K. BOMAN,
A. C. HARDY-BESSARD, A. BURGES, J. MÄENPÄÄ, E. PUJADE-LAURINE, J. PFISTERER, M. GROPP, A. STAEHLE,
P. WIMBERGER, C. JACKISCH, B. SCHMALFELDT, A. BELAU, S. LOIBL, K. WOLLSCHLAEGER, U. CANZLER & J. ROCHON
- 226 "Dose dense" chemotherapy in ovarian cancer
P. A. VASEY
- 233 What is the role of dose-dense therapy?
M. E. L. VAN DER BURG, A. VAN DER GAAST, I. VERGOTE, C. W. BURGER,
H. C. VAN DOORN, R. DE WIT, G. STOTER & J. VERWEIJ
- 241 Treatment of recurrent disease: randomized trials of monotherapy versus combination chemotherapy
A. GONZÁLEZ-MARTÍN
- 247 Randomized single-agents trials in recurrent epithelial ovarian cancer
C. SESSA & S. MARSONI
- 252 New agents for the treatment of ovarian cancer: the next generation
J. DUPONT, C. AGHAJANIAN, P. SABBATINI & D. R. SPRIGGS
- 258 Trial design for testing new therapies in ovarian cancer
E. A. EISENHAUER

Listed in
INDEX MEDICUS

The *International Journal of Gynecological Cancer* is also indexed in the
Science Citation Index, Current Contents/Clinical Medicine, Scisearch,
Research Alert, CABS, Chemical Earth Science, Physicals, and the Excerpta
Medica database EMBASE.

- 266 Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets
E. A. BOYCE & E. C. KOHN
- 274 New tumor markers: CA125 and beyond
R. C. BAST, JR, D. BADGWELL, Z. LU, R. MARQUEZ, D. ROSEN, J. LIU, K. A. BAGGERLY, E. N. ATKINSON, S. SKATES,
Z. ZHANG, A. LOKSHIN, U. MENON, I. JACOBS & K. LU
- 282 Interleukin-10 and *Fas* polymorphisms and susceptibility for (pre)neoplastic cervical disease
M. ZOODSMA, I. M. NOLTE, M. SCHIPPER, E. OOSTEROM, G. VAN DER STEEGE,
E. G. E. DE VRIES, G. J. TE MEERMAN & A. G. J. VAN DER ZEE
- 291 Is there still a role for hormonal therapy?
M. A. BOOKMAN
- 298 Ovarian cancer: is the news good enough?
A. POVEDA

This supplement is supported by
an unrestricted educational grant
from Bristol Myers Squibb



Bristol-Myers Squibb, s.L.